Sam Brusco, Associate Editor04.18.22
AtriCure has launched its EnCompass Clamp, part of the Isolator Synergy ablation system, in the U.S. The technology recently earned U.S. Food and Drug Administration (FDA) clearance to ablate cardiac tissue during cardiac surgery.
Designed to make concomitant surgical ablation more efficient, the EnCompass Clamp includes parallel closure, uniform pressure, and custom Synergy radiofrequency (RF) power. It can be placed more easily using a magnetic guide, helping minimize tissue dissection.
“The EnCompass Clamp provides a simpler and faster approach to ablating the heart in open-chest procedures,” said Michael Carrel, president and CEO of AtriCure told the press. “We are passionate about innovation, leading to high-quality options for our physician partners. We believe the EnCompass Clamp will meet the unique needs of surgeons who are performing closed-atrium cardiac surgery.”
“This new device has become an invaluable part of the way I perform surgical ablation,” added Dr. Prem Samuel, a cardiothoracic surgeon at Midwest Heart & Vascular Specialists, Kansas City, Mo. “It is used with minimal dissection and creates lesions around the pulmonary veins and the entire posterior wall of the left atrium without opening the atrium, all in a single pass through the transverse and oblique sinuses. I’ve seen firsthand the gains in efficiency that the EnCompass Clamp can bring to my practice and patients.”
Designed to make concomitant surgical ablation more efficient, the EnCompass Clamp includes parallel closure, uniform pressure, and custom Synergy radiofrequency (RF) power. It can be placed more easily using a magnetic guide, helping minimize tissue dissection.
“The EnCompass Clamp provides a simpler and faster approach to ablating the heart in open-chest procedures,” said Michael Carrel, president and CEO of AtriCure told the press. “We are passionate about innovation, leading to high-quality options for our physician partners. We believe the EnCompass Clamp will meet the unique needs of surgeons who are performing closed-atrium cardiac surgery.”
“This new device has become an invaluable part of the way I perform surgical ablation,” added Dr. Prem Samuel, a cardiothoracic surgeon at Midwest Heart & Vascular Specialists, Kansas City, Mo. “It is used with minimal dissection and creates lesions around the pulmonary veins and the entire posterior wall of the left atrium without opening the atrium, all in a single pass through the transverse and oblique sinuses. I’ve seen firsthand the gains in efficiency that the EnCompass Clamp can bring to my practice and patients.”